# Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs | This GLP In 1,391 matched pairs with sickle cell disease and type 2 diabetes, GLP-1 use came with fewer cardiovascular events (HR 0.61) and fewer vaso-occlusive crises (HR 0.64). Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Sickle Cell Disease? One Cohort, 1,391 Pairs Vaso-occlusive crises ran 36% lower among GLP-1 users in the only matched cohort that exists, but kidney progression, which matters as much in this disease, was measured far too imprecisely to call either way. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read 1,391 matched pairs, 12 months · cardiovascular events · 0.61 · stroke · 0.47 · pain crises · 0.64 · kidney disease · 1.26 · hypoglycemia · 1.10 · Dashed line marks no difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A matched cohort of 1,391 pairs with both sickle cell disease and type 2 diabetes compared GLP-1 users against non-users over 12 months. - Major cardiovascular events were lower (HR 0.61, 95% CI 0.49-0.76) and so were vaso-occlusive pain crises (HR 0.64, 95% CI 0.45-0.91). - Stroke came in at HR 0.47, with an interval of 0.23 to 0.97 that clears 1 by three hundredths. - No difference appeared in hypoglycemia or in progression to chronic kidney disease, where the interval reaches 1.95. Nobody has run a trial to find out, and the one matched cohort that exists points favorably rather than conclusively. Across 1,391 pairs with both sickle cell disease and type 2 diabetes, followed for a year, painful vaso-occlusive crises occurred 36% less often among GLP-1 users, at a hazard ratio of 0.64 [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease#ref-1). People with this disease are largely absent from the trials that built the evidence base for these drugs, and 84.5% of the cohort were Black. That is a group underrepresented in almost every study covered here, including the access picture in [uptake after a heart attack or stroke](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke). The cardiovascular findings are roughly what this drug class produces elsewhere. Major adverse cardiovascular events came in at a hazard ratio of 0.61 (95% CI 0.49–0.76), and stroke at 0.47 (95% CI 0.23–0.97). The novel result is the one specific to the disease. Vaso-occlusive crises — the painful episodes that define sickle cell disease and drive most of its hospital admissions — occurred 36% less often among GLP-1 users (HR 0.64, 95% CI 0.45–0.91). That is not a cardiovascular benefit restated; it is a claim about the mechanism of the underlying disease, and there is no obvious precedent for it in this drug class. Whether an anti-inflammatory route could plausibly carry such an effect is the open question. The SELECT inflammation substudy is where it is usually raised, because semaglutide cut high-sensitivity CRP by 37.8% at 104 weeks against placebo [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-sickle-cell-disease#ref-2). That is a marker rather than an outcome, read here in [the inflammation substudy](https://thisglp.com/research/do-glp1-drugs-reduce-inflammation). Two results did not move, and one of them matters a lot Hypoglycemia showed no difference (HR 1.10), which is reassuring in a group already managing diabetes. Progression to chronic kidney disease also showed no difference, at HR 1.26 with an interval running to 1.95. Kidney disease is a leading cause of death in sickle cell disease, and an interval whose upper bound approaches a doubling is not evidence of safety — it is an estimate too imprecise to rule much out in either direction. Two limits shape how far any of this travels. Everyone in the study had type 2 diabetes as well as sickle cell disease, which is an unusual combination and not the typical patient with either condition. The stroke interval is the other limit, because 0.23 to 0.97 excludes 1 by a margin thin enough that a modest amount of unmeasured confounding would erase it. The same caution applies with equal force to [the glaucoma comparison](https://thisglp.com/research/do-glp1-drugs-cause-glaucoma), where the upper bound was 0.96. What makes this worth reporting despite those limits is that the alternative is nothing. Rare-disease populations rarely accumulate enough participants for a trial, and a matched cohort of 1,391 pairs is a substantial body of evidence by the standards of the field it sits in. A result that would be preliminary in type 2 diabetes is, here, among the better evidence available — which is also true of the disease-specific findings in [the Crohn's disease cohort](https://thisglp.com/research/do-glp1-drugs-help-crohns-disease). ## Frequently asked Do GLP-1 drugs reduce sickle cell pain crises? This cohort found 36% fewer vaso-occlusive crises among users (HR 0.64, 95% CI 0.45-0.91). It is observational, so it establishes an association rather than an effect, but it is a disease-specific finding without obvious precedent. Is it safe for the kidneys? The study could not tell. Progression to chronic kidney disease showed no significant difference, but the interval ran from 0.82 to 1.95, which is too wide to rule out meaningful harm or benefit. Does this apply to sickle cell disease generally? Not directly. Every participant also had type 2 diabetes, which is an unusual combination and not representative of most people with sickle cell disease. ## Sources 1. \[1\] Nguefang GL, Boateng S, Gyabaah S, Issaka Y, et al. (2026). Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis Orphanet Journal of Rare Diseases. [PMID 41904481](https://pubmed.ncbi.nlm.nih.gov/41904481/) 2. \[2\] Plutzky J, Bogdański P, Colhoun HM, Dağdelen S, et al. (2026). Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis Circulation. [PMID 42610271](https://pubmed.ncbi.nlm.nih.gov/42610271/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)